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Dietary supplements containing L-arginine have been marketed with the purpose of increasing vasodilatation, and
thus, blood and oxygen supply to the exercising muscle. The present study evaluated the acute effect of L-arginine
supplementation on indicators of NO production, nitrite (NO2
- ) + nitrate (NO3
- ) (NOx), in healthy subjects. Plasma
concentrations of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have also been
addressed. Seventeen healthy males participated in a randomized, double-blind, placebo-controlled study. Blood
samples were drawn from a left antecubital vein at baseline (T0). Afterwards, subjects were randomly submittedto
6 g of oral L-arginine supplementation (as L-arginine hydrochloride) or placebo (as corn starch); afterwards, the
subjects remained at rest in supine position and blood samples were drawn again at 30 (T1), 60 (T2), 90 (T3) and
120 minutes (T4) after supplementation. To analyze NO production, NO3
- was converted to NO2
- by nitrate reductase,
followed by the derivatization of NO2
- with 2,3-diaminonaphthalene. NOx, ADMA and SDMA were analyzed using a
high-performance liquid chromatography system and monitored with a fluorescence detector. Two-way ANOVA
with repeated measures showed no significant changes in NOx concentrations on the L-arginine group as
compared to placebo group at any of the fivetime points (T0: 17.6 ± 3.9 vs 14.6 ± 2.3 μmol/L; T1: 15.8 ± 2.4 vs
14.3 ± 1.7 μmol/L; T2: 16.8 ± 4.9 vs 13.7 ± 2.7 μmol/L; T3: 16.7 ± 3.9 vs 14.6 ± 2.1 μmol/L; T4: 15.1 ± 2.8 vs
13.5 ± 3.5 μmol/L). Furthermore, plasma levels of ADMA and SDMA were not statistically significant between the
L-arginine and placebo groups at T0 (0.43 ± 0.19 vs 0.39 ± 0.15 μmol/L and 1.83 ± 1.13 vs 1.70 ± 0.62 μmol/L),
respectively. In conclusion, acute L-arginine supplementation does not increase plasma concentration of NOx in
healthy individuals with normal plasma concentrations of ADMA.
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HPLCIntroduction
Many supplements have been introduced in the market
with the purpose of enhancing athletes’ performance [1].
Most of these supplements allegedly help athletes tolerate
a higher degree of heavy training by helping athletes re-
cover faster during intense sport training [2]. Recently,
supplements containing L-arginine have been introduced* Correspondence: alvares@iq.ufrj.br
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reproduction in any medium, provided the orin the market claiming to promote vasodilatation by in-
creasing nitric oxide (NO) production via nitric oxide syn-
thase (NOS) activation. This vasodilatation would favor an
increase perfusion as well as a higher nutrient and oxygen
delivery to the active muscles during exercise, enhancing
protein synthesis and muscle recovery [2].
L-arginine is considered a semi-essential amino acid
because the body normally produces it in sufficient
amounts. However, supplementation may be needed in
special conditions such as malnutrition, excessive am-
monia production, burns, infections, peritoneal dialysis,
rapid growth, urea synthesis disorders, and/or sepsis [3].
Physiological concentrations of L-arginine in healthy
individuals are enough to saturate endothelial NOS,
which is ~ 3 μmol/L. Therefore, supplementary L-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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consequently, no further NO production should occur.
However, there is evidence describing the NO-mediated
biological effects associated with L-arginine supplemen-
tation despite the fact that nitric oxide synthase (NOS)
is theoretically saturated with the physiological concen-
tration of L-arginine—hence the condition known as the
‘L-arginine paradox’ [4].
Early evidence suggests that L-arginine supplementa-
tion may help treat individuals with atherosclerosis risk
factors, such as hypercholesterolemia, hypertension, dia-
betes mellitus, kidney failure, hyperhomocysteinemia,
smoking, and aging—all of which are conditions that are
associated with reduced NO biosynthesis [5-9]. Böger R.,
[10] had shown that plasma levels of asymmetric
dimethylarginine (ADMA), an endogenous NOS inhibi-
tor, are increased approximately 2–3 fold in the patho-
physiological conditions associated with cardiovascular
disease. For this reason, elevated ADMA concentration
may be one possible explanation for endothelial dysfunc-
tion and decreased NO synthesis in this disease cluster.
Therefore, it appears that only subjects with poor NO
synthesis are likely to benefit from L-arginine
supplementation.
Despite the theory regarding L-arginine supplementa-
tion improving vasodilatation from increased NO pro-
duction, a recent review [2] about the ergogenic effect of
L-arginine supplementation in healthy subjects shows
that there were only five studies that evaluated exercise
performance after acute L-arginine supplementation,
three of which reported significant improvements. Be-
sides the improvements observed in physical perform-
ance, the authors of these studies did not measure the
underlying mechanism that could explain how the
results obtained may have been due to increased NO
production.
Bailey et al., [11] observed significant increases in the
time to task failure with concomitant reductions in the
O2 cost of moderate-intensity cycle exercise and slow
oxygen uptake component amplitude on the group sup-
plemented with 6 g of L-arginine, 1 h before a series of
moderate- and severe-intensity exercise bouts for 3 days.
Stevens et al., [12] observed significant increase in peak
torque, total work and fatigue index after supplement-
ing with a product containing 6 g of L-arginine in
three equal aliquots at 45, 30 and 10-min periods be-
fore isokinetic dynamometer exercise. Buford and Koch,
[13] observed significant improvement of average
power during repeated sets of supra-maximal exercise
during cycle ergometer on the group that consumed
6 g of L-arginine.
Based on the theory that physiological concentrations
of L-arginine are enough to saturate endothelial NOS
and no further NO production should occur in healthyindividuals, it is our hypothesis that there should be no
change inplasma concentration of NO2
- and NO3
- as a re-
sult of L-arginine supplementation when compared to
placebo.
Due to the fact that other studies have demonstrated
vascular and exercise performance benefits after L-
arginine supplementation in healthy individuals [2,14],
the question still remains as to whether this effect is
NO-mediated. Therefore, in order to test the claim that
L-arginine supplementation may increase NO synthesis,
the present study was conducted to identify the acute
effects of L-arginine supplementation on indirect mar-
kers of NO synthesis—NO2
- and NO3
- . It is to point out
that, contrary to the present study, other studiesthat
evaluated the effect of L-arginine supplementation on
NO synthesis at rest have methodological limitations
[15] (e.g.: They did not control diet for food contain
NO2
- and NO3
-), which may cause flaws in the results.
The plasma levels of ADMA and SDMA at the begin-
ning of the study have also been addressed.
Methods
Subjects
Seventeen healthy males (25.5 ± 3.5 yr, 78.7 ± 10.5 kg;
176.1 ± 7.5 cm and 25.3 ± 2.3 kg.m-2 BMI) were recruited
to participate in the study. All subjects were fully
informed of the nature and purpose of the investigation
and gave their written consent to participate. The exclu-
sion criteria for participation in the study were any
known cardiovascular, pulmonary or metabolic diseases
(asthma, diabetes, hypertension, dyslipidemia etc.), and
the use of nutritional and pharmacological ergogenics.
All experimental procedures were performed in accord-
ance with the ethical standards of the Helsinki Declar-
ation and were approved by the Institutional Ethics
Committee of the Hospital Universitário Clementino
Fraga Filho (protocol # 0118.0.197.000-10) from Rio de
Janeiro, Brazil.
Experimental design
In a randomized, double-blind and placebo-controlled
study, subjects reported to the laboratory. Blood samples
were drawn from an antecubital forearm vein at baseline
after a ten-minute period of quiet rest in supine position.
Afterwards, subjects were randomly divided into either a
placebo or an L-arginine group and rested again in su-
pine position in a quiet room. Blood samples were
drawn again at 30 (T0), 60 (T1), 90 (T2) and 120 min-
utes (T4) after supplementation (see Figure 1). During
this period, the subjects consumed no food and drink.
Dietary control
One day before conducting the study, the subjects were
oriented as to the NO2
- and NO3
- content of foods and
Figure 1 Summary of experimental design.
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NO2
- and NO3
- . A list describing foods and groups of
food to be avoided and to be preferred was distributed
to the subjects, in order to simplify their dietary choices
for low NO2
- and NO3
- foods for the 24-hour period prior
to the study. In short, the subjects were advised to avoid
vegetable products, such as spinach and squash, which
contain the highest amounts of NO3
- per serving. Sweets,
nuts, fats and oils contain very little NO3
- per serving
and were thus permitted. Red meat (beef, pork, lamb,
mutton, and liver) and bean products contain the high-
est amounts of dietary NO2
- per serving and were to be
avoided. Negligible sources of dietary NO2
- are found in
cottage cheese, fats such as butter or margarine, and
various fruit juices. This dietary orientation was based
on a list developed to estimates of dietary NO2
- and NO3
-
[16]. Adherence to the diet was controlled by twenty-
four-hour recall conducted upon arrival for the study, in
which each subject was interrogated as to their dietary
intake for the 24 h period prior to arrival for the study.
Further analysis of energy intake and macronutrients (as
a percentage of total energy) from the twenty-four-hour
recall of each subject of both L-arginine and placebo
groups was performed by using a nutrition analysis soft-
ware program (dietWin Professional 2008 for windows,
version 2.0, Porto Alegre, RS, Brazil).
Supplementation
Ten minutes after baseline blood sample, all subjects
were orally administered either 6 g of encapsulated L-
arginine hydrochloride or placebo (as corn starch) in
identical forms with 400 mL of H2O Milli-Q in a
double-blind and randomized manner. We chose to pro-
vide 6 g of L-arginine, because such a dose would be
well-tolerated when consumed orally, and was reported
to increase vasodilatation [17].
Nitric oxide production
The blood was drawn from antecubital veins and col-
lected in EDTA-containing tubes, and then immediatelycentrifuged at 3000 g for 10 min at 4°C in order to separ-
ate the plasma, before storing it at −80°C for later ana-
lysis. NO production was assayed by measuring plasma
NO2
- +NO3
- (NOx) as previously described by Li et al.
[18]. In brief, plasma was diluted in a proportion of 1:10
and 1:100 in order to analyze NO2
- and NO3
- , respect-
ively. After dilution, 1 mL of each sample were filtered
using a 10-kDa cutoff ultrafilter (Vivaspin 2, GE Health-
careW) at 14000 g for 15 min to remove high-molecular
weight proteins. NO3
- was converted to NO2
- enzymati-
cally by nitrate reductase EC 1.6.6.2 (Roche Diagnostics,
Mannheim, Germany) from Aspergillus species. The so-
lution, which consisted of 200 μL of sample, 120 μM
NADPH and 2 μM FAD, was incubated at room
temperature for 1 h. Following the conversion of NO3
- to
NO2
- , the sample was incubated at 24°C with 316 mM
2,3-diaminonaphthalene to convert NO2
- into the highly
fluorescent 2,3-naphthotriazole followed by addition of
2.8 M NaOH and immediately analyzed by high-
performance liquid chromatography (HPLC). The HPLC
device was equipped with a 5-μm reversed-phase C8 col-
umn DiscoveryW (150 x 4,6 mm, I.D.) guarded by a 40-
μm reversed-phase C18 guard column AscentisW (50 x
4,6 mm, I.D.) and a fluorescence detector model RF-
10AXL (ShimadzuW) monitoring excitation and emission
wavelengths at 375 nm and 415 nm, respectively. Both
columns were obtained from Supelco (Bellefonte, PA,
USA). The mobile phase (1.0 mL/min) was 15 mM so-
dium phosphate buffer (pH 7.5) and methanol.
Oxidation of NO via several metabolic reactions
results in the formation of nitrite (NO2
-) and nitrate
(NO3
-) as the two major end products [19]. The principal
oxidation product of NO synthesis in aqueous solutions
(in the absence of biological constituents such as hemo-
proteins) is NO2
- . The further oxidation to NO3
- requires
the presence of additional oxidizing species such as oxy-
hemoproteins [20]. For example, NO is quickly oxidized
to NO2
- via autoxidation in aqueous solutions, such as
biological fluids, and may react with superoxide anions
to produce peroxynitrites. In the presence of heme
groups in proteins such as hemoglobin and myoglobin,
NO reacts with oxyhemoglobin to produce metahemo-
globin and NO3
- . Therefore, measurement of NO2
- and
NO3
- in various biological fluids turned out to be the
most suitable, practical and reliable non-invasive method
to assess systemic NO synthesis in vivo [19].
Plasma amino acids
The amino acids L-arginine, L-citrulline and L-ornithine
were analyzed as previously described by Wu and Mei-
ninger [21]. In brief, 50 μL of plasma was mixed with 50
μL of 1.5 M perchloric acid (v/v) to remove proteins.
After 2 min at room temperature, 1.125 mL H2O and 25
μL potassium carbonate was added. The tubes were
Table 1 Subject’s baseline characteristics
L-Arg (N= 9) Pla (N = 8)
Age (yr) 26.0 ± 4.6 24.9 ± 1.7
Height (cm) 175.4 ± 7.7 177.0 ± 7.6
Body weight (kg) 79.3 ± 12.5 78.1 ± 8.4
BMI (kg.m-2) 25.7 ± 2.4 24.9 ± 2.3
Body fat (%) 14.4 ± 5.6 16.4 ± 2.5
ADMA (μmol/L) 0.43 ± 0.19 0.39 ± 0.15
L-arginine/ADMA ratio 453 ± 282 438± 272
SDMA (μmol/L) 1.83 ± 1.13 1.70 ± 0.62
The values are mean ± standard deviation. L-Arg = L-arginine supplemented
group; Pla = Placebo group.
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was mixed with 25 μL of the o-phthaldialdehyde (OPA)
reagent solution (v/v) for 1 min. The solution derivatized
was immediately analyzed by HPLC. The HPLC device
was equipped with a 3-μm reversed-phase C18 column
KromasilW (150 x 4.6 mm, I.D.) guarded by a 40-μm
reversed-phase C18 guard column AscentisW (50 x
4.6 mm, I.D.) and a fluorescence detector model RF-
10AXL (ShimadzuW) monitoring excitation and emission
wavelengths at 340 nm and 455 nm, respectively. These
chromatographic methods are highly sensitive, specific,
and accurate, as well as provide a useful tool to study
the L-arginine—NO pathway.
ADMA and SDMA analysis
The plasma concentrations of ADMA and SDMA were
analyzed as previously described by Wu and Meininger
[21]. In brief, 200 μL of plasma was mixed with 100 μL of
1.5 M perchloric acid (v/v) to remove proteins, followed
by 50 μL of 2 M potassium carbonate and 700 μL of phos-
phate buffer (pH 7.0). The whole solution was loaded into
a solid-phase extraction column (Oasis MCX) and the elu-
tion solvent was removed using a sample concentrator
system (Savant SpeedVac Concentrator, Thermo Fisher
Scientific Inc.). The residues were suspended in 200 μL
H2O. The sample (15 μL) was mixed with 15 μL of the
OPA reagent (v/v) for 1 min. The solution derivatized was
immediately analyzed by HPLC. The HPLC device was
equipped with a Nucleosil 100–5 C6H5 column (250 x
4.6 mm, I.D; Manchery Nagel, Easton, PA) and a fluores-
cence detector model RF-10AXL (ShimadzuW) monitored
excitation and emission wavelengths at 340 nm and
455 nm, respectively. All chromatographic procedures
were performed at room temperature.
Statistical analysis
A Two-way ANOVA with repeated measures on two fac-
tors (2 x 5; group x time) was utilized to identify differ-
ences in NOx and plasma amino acids at each time
point. Calculation of the integrated plasma NOx concen-
tration [area under the curve (AUC)] was determined by
the use of a trapezoidal method (baseline NOx concen-
tration: y = 0). Unpaired Student t-test was utilized to
identify differences in plasma concentrations of ADMA,
SDMA and L-arginine/ADMA ratio at the onset of the
study. Statistical significance was set at the 0.05 level of
confidence. All analyses were performed using GraphPad
Prism version 5.00 for Windows (GraphPad Software,
San Diego California USA).
Results
Subject characteristics
At the study onset there were no significant differences
between the randomly assigned placebo versus L-arginine groups with respect to age, height, body weight,
BMI, body fat (see Table 1).
Dietary control
Based on the evaluation of the twenty-four-hour recall,
all subjects of both the L-arginine and placebo groups
had apparently adhered to the dietary orientation and
avoided all foods listed as high in NO2
- and NO3
- .
There was no significant difference in energy intake
and percentage of macronutrients before 24 h of be-
ginning the study between L-arginine and placebo
groups (2663 ± 508.5 vs 2905 ± 641.6 kcal; 52.9 ± 6.3 vs
53.6 ± 5.8% carbohydrates; 21.6 ± 4.8 vs 21.7 ± 5.1% pro-




- (NOx) concentrations at each time
point are depicted in Figure 2. No significant differences
were found between groups at any time point. Figure 3
presents the data for the total integrated NOx AUC
during the 120 min post supplementation period. The
integrated AUC revealed that despite a 15% higher, the
L-arginine supplementation did not resulted in greater
NOx response than placebo group over the time
(P> 0.05).
Plasma amino acids
The plasma concentrations of L-arginine, L-citrulline and
L-ornithine at each time point are depicted in Table 2. No
significant difference between groups was observed at
baseline. Plasma L-arginine increased significantly at
30 min (209.9± 39.1 vs 123.3 ± 44.6 μmol/L, P< 0.001),
60 min (192.3± 51.3 vs 133.4 ± 36.0 μmol/L, P< 0.05),
90 min (204.9± 55.1 vs 138.8 ± 42.2 μmol/L, P< 0.05) and
120 min (224.7± 57.8 vs 150.8 ± 34.8 μmol/L, P< 0.01)
after supplementation in the L-arginine group, when com-
pared to the placebo group (see Figure 4). No significant
change was observed between groups in plasma L-
citrulline and L-ornithine at any time point.
Figure 2 Plasma NOx concentrations (μmol/L). No significant
change was observed between groups at any time point. L-Arg= L-
arginine supplemented group; Pla = Placebo group.
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At the onset of the study, there were no significant dif-
ferences in plasma levels of ADMA, SDMA and L-
arginine/ADMA ratio between the randomly assigned
placebo versus L-arginine groups (0.43 ± 0.19 vs
0.39 ± 0.15 μmol/L and 1.83 ± 1.13 vs 1.70 ± 0.62 μmol/L)
(see Table 1).Discussion
Dietary supplements containing the semi-essential
amino acid L-arginine (the only substrate of NOS) have
been introduced in the market, claiming to promote
vasodilatation by increasing production of NO. In the
present study, we found that in healthy subjects 6 g of
oral L-arginine supplementation did not stimulate an in-
crease in NO production when compared with the pla-
cebo group. Additionally, no significant increases were
observed in plasma L-citrulline, which is the by-product
of NO synthesis from L-arginine. Furthermore, no sig-
nificant differences in plasma concentrations of ADMAFigure 3 Total integrated NOx area under curve during the
120 min post supplementation period. No significant change was
observed between groups over the time. L-Arg = L-arginine
supplemented group; Pla = Placebo group.and SDMA at onset of the study were observed between
the L-arginine and placebo groups.
Several studies had showed no significant difference in
NO production (measured by NO2
- and NO3
-) after L-
arginine supplementation [22-24]. Liu et al. [22] did not
observe any significant differences in plasma NO2
- and
NO3
- concentrations after orally supplementing ten
healthy male athletes with 6 g of L-arginine (as free
form) or placebo for 3 days. Koppo et al. [23] observed
no significant difference in urinary NO2
- and NO3
- after
14 days of supplementing seven physically active healthy
males with 7.2 g of L-arginine hydrochloride (3 × 3 cap-
sules of 805 mg), and Tang et al. [24] also did not
observed any significant difference on NO synthesis
(measured by plasma NO2
- and NO3
-) in eight healthy
young men after an single dose of 10 g of L-arginine.
Since all subjects of these studies were submitted to ex-
ercise, the results of these studies are not surprising due
to the very nature of the underlying mechanism of NO
synthesis: vascular shear stress is considered the main
stimulus for endothelial NO production during exercise
[25]. Therefore, there should theoretically be no need for
supplementary L-arginine to synthesize NO during
exercise.
Regarding studies at rest condition, Blum et al. [26]
investigated the effects of oral L-arginine (9 g daily for
one month) on NO bioactivity in 10 healthy postmeno-
pausal women. After the supplementation period, the
authors observed no significant difference in serum NO2
-
and NO3
- concentrations. In another study, Evans et al.
[27] also did not find significant differences in serum
NO2
- and NO3
- concentrations after submitting twelve
healthy subjects to take L-arginine for 1-week periods at
daily doses of 3, 9, 21, and 30 g. Schwedhelm et al., [28]
published a study with the purpose of investigating the
pharmacokinetic and pharmacodynamics properties of
oral L-arginine with regard to NO metabolism. Twenty
healthy subjects were submitted to two doses of L-
arginine supplementation (1 g of arginine sustained-
release tree times per day or 1.6 g of immediate-release
arginine two times per day) for 7 days. At baseline and
on day 7, a single dose of L-arginine supplementation
(half of the total daily dose, respectively) was adminis-
tered and blood samples were drawn at 0, 0.5, 1, 2, 3, 4,
6, 8, 12, 16 and 24 h after supplementation. The authors
observed no significant differences in urinary excretion
of nitrate at any time point, despite increases in plasma
L-arginine concentrations after the supplementation
(Tmax = 3.7 ± 1.3 h for arginine sustained-release and
0.7 ± 0.1 h for arginine immediate-release). In the
present study, the plasma L-arginine concentrations
increased significantly after 30 min of L-arginine supple-
mentation when compared to placebo group, and main-
tained high throughout the study period. Furthermore,
Table 2 Values of plasma amino acids (μmol/L) at −10, 30, 60, 90 and 120 minutes post-supplementation
Amino acid L-Arg (n =9) Pla (n =8)
−10 30 60 90 120 −10 30 60 90 120
L-citrulline 57.4 125.2 75.2 89.7 82.2 56.2 76.9 66.2 75.9 79.8
±31.2 ±136.3 ±45.4 ±92.9 ±78.0 ±28.1 ±26.3 ±43.0 ±53.9 ±63.0
L-arginine 151.7 209.9 192.3 204.9 224.7 146.2 123.3 133.4 138.8 150.8
±33.9 ±39.1*** † ±51.3* ±55.1* ±57.8* a ±44.3 ±44.6 ±36.0 ±42.2 ±34.8
L-ornithine 127.5 153.2 154.0 143.1 147.0 93.4 119.8 101.1 105.5 110.4
±87.1 ±84.9 ±65.7 ±55.9 ±65.4 ±23.7 ±88.8 ±49.6 ±59.9 ±59.2
The values are mean ± standard deviation. The symbols ***(P< 0.001), **(P< 0.01) and *(P< 0.05) denotes significantly different from placebo at same time point; a
denotes significantly different from time −10. L-Arg = L-arginine supplemented group; Pla = Placebo group.
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centrations of L-ornithine and L-citrulline at any time
point between the groups.
It is important to point out that, contrary to the
present study, neither of the above mentioned studies
controlled the intake of food rich in NO2
- and NO3
- from
subject’s diet before or during the study. Most NO2
- and
NO3
- comes from diet (vegetable products contain the
highest levels of NO3
- ; meat and bean products contain
the highest levels of NO2
-), which may alter the results of
the analysis. Thus, endogenous synthesis of NO may not
be adequately measured by NO2
- and NO3
- in plasma and
urine if the diet is not controlled.
Measurement of NO2
- and NO3
- in various biological
fluids turned out to be the most suitable, practical and
reliable non-invasive method to assess systemic NO syn-
thesis in vivo [19]. In the present study, NO synthesis
was quantified by measuring plasma NO2
- +NO3
- (NOx)
via high-performance liquid chromatography. Most of
the studies [22-24] had analyzed NO synthesis by using
Griess reaction. The acidic conditions under which
experiments using Griess reaction are conducted favor
the formation of S-nitroso compounds from NO2
- and
reduced thiols. Thus, the measurement of NO2
- and NO3
-
in biological fluids by assays based on the Griess isFigure 4 Plasma concentration of L-arginine. The symbols ***
(P< 0.001), **(P< 0.01) and *(P< 0.05) denotes significantly different
from placebo; a(P< 0.01) denotes significantly different from 0
minutes. L-Arg = L-arginine supplemented group; Pla = Placebo
group.subject to interference by many substances acting at dif-
ferent places in the Griess reaction and the following
spectrophotometric measurement in the same wave-
length (normal absorbance at 540 nm). Therefore, stud-
ies using Griess reaction to detect stable metabolites
(NO2
- and NO3
-) to measure NO synthesis may have sig-
nificant methodological limitations, as compared to
fluorometric techniques associated with HPLC.
Bailey et al. [11] observed significant increases in
plasma NO2
- after supplementing nine healthy recre-
ationally active men with a supplement that contained
6 g of L-arginine (dissolved in 500 mL of water) as com-
pared to placebo. It is important to note that this study
associated other amino acids besides L-arginine, includ-
ing L-citrulline (quantities not expressed in the study),
which have been shown to increase NO production, as
measured by plasma concentrations of NO2
- [29] and
urinary excretion of NO3
- and cGMP [28]. Interestingly,
the authors did not measure plasma NO2
- at baseline;
they had just done so 1 hour after supplementation,
which is a major methodological limitation, since it is
not known whether there were any differences in the
samples prior to supplementation. Furthermore, taking
into consideration that diet can influence nitrite plasma
concentrations, no dietary control to limit the consump-
tion of foods rich in NO2
- and NO3
- was conducted.
Others studies also have showed improvements in NO
production by using L-arginine supplementation [30-33].
However, all of these studies had administered L-arginine
in subjects with some cardiovascular risk factors or car-
diopathy. It appears that L-arginine is a limiting factor
for NO synthesis in patients at risk for atherosclerosis,
but not for healthy individuals [34]. Therefore, L-
arginine supplementation may be necessary only for indi-
viduals with atherosclerosis risk factors.
Among the possible explanations for this phenomenon
is the presence of high levels of asymmetric dimethylargi-
nine (ADMA), an endogenous NOS inhibitor. Higher con-
centrations of ADMA were encountered in individuals
with atherosclerosis, as well as in individuals with athero-
sclerosis risk factors, such as hypercholesterolaemia,
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mocysteinaemia, smoking and aging [10]. Physiological
levels of L-arginine and the presence of normal concentra-
tions of ADMA saturate the endothelial NOS enzyme,
promoting NO production. In these conditions, L-
arginine supplementation does not affect enzyme activity.
In contrast, in the presence of elevated plasma concentra-
tions of ADMA the endothelial NOS activity diminishes,
resulting in lower physiological levels of NO production.
SDMA has no effect on NOS activity but may compete
with L-arginine for the y + transport system [35]. Under
these conditions, L-arginine supplementation may re-
establish the L-arginine/ADMA ratio in order to activate
endothelial NOS [4]. Therefore, L-arginine supplementa-
tion may exert a beneficial effect on vascular function.
In the present study, we observed no significant differ-
ence in plasma concentrations of ADMA, SDMA and L-
arginine/ADMA ratio at baseline between the groups.
This finding may explain the absence of significant
changes in NO production after L-arginine supplemen-
tation. The baseline plasma concentrations of ADMA
observed in the present study are similar to previous
studies in healthy subjects which reported ADMA con-
centrations ranging between 0.3 and 0.9 μmol/L [36-38].
Therefore, it may be speculated that there should be no
further increase in NO production after L-arginine sup-
plementation in subjects with normal levels of ADMA.
Böger et al., [34] observed that plasma ADMA levels
were significantly higher in hypercholesterolemic sub-
jects than in normocholesterolemic control subjects
(2.17 ± 0.15 and 1.03 ± 0.09 μmol/L, respectively); and
the higher levels of ADMA was associated with reduced
NO synthesis. Therefore, it appears that high plasma
ADMA concentrations may inhibit NOS enzyme, but
low or normal plasma ADMA concentrations do not
affect NO synthesis.
In conclusion, L-arginine supplementation does not
increase NO production in healthy subjects with normal
plasma ADMA concentrations. Therefore, it is not ad-
visable to recommend dietary supplements containing
L-arginine for the purposes of increasingacutely NO
production in healthy subjects. This result does not dis-
card the possible effect of L-arginine on NO production
in individuals with pathophysiologicalconditions (e.g.:
hypercholesterolaemia, hypertension, diabetes mellitus,
kidney failure, hyperhomocysteinaemia, smoking and
aging) and long-term studies are needed to identify
whether L-arginine may provide some benefit.Abbreviations
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